Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis

Abstract Body weight loss of ≥ 10% improves the metabolic derangements and liver disease in the majority of non-alcoholic steatohepatitis (NASH) patients, suggesting metabolic modulators may be effective in controlling disease. The pharmacodynamics of ALT-801, a GLP-1/glucagon receptor dual agonist...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: John J. Nestor, David Parkes, Michael Feigh, John J. Suschak, M. Scott Harris
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Portfolio 2022-04-01
Edice:Scientific Reports
On-line přístup:https://doi.org/10.1038/s41598-022-10577-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky